Orgenesis's basic earnings per share (Basic EPS) for the
three
months ended in Dec. 2021 was $-0.20.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.74.
Orgenesis's EPS (Diluted) for the
three
months ended in Dec. 2021 was $-0.20.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.74.
Orgenesis's EPS without NRI for the
three
months ended in Dec. 2021 was $-0.20.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2021 was -0.74.
During the past 3 years, the average EPS without NRIGrowth Rate was 19.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Orgenesis's highest 3-Year average EPS without NRI Growth Rate was 19.70% per year. The lowest was -611.40% per year. And the median was -2.70% per year.
Orgenesis EPS (Basic) Historical Data
The historical data trend for Orgenesis's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
EPS (Basic)
-1.28
-1.43
-1.77
0.29
-0.74
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
EPS (Basic)
-2.27
-0.01
-0.11
-0.42
-0.20
Orgenesis EPS (Basic) Calculation
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Orgenesis's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Orgenesis EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Orgenesis's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.25(11.9%) Volume: 130,258 9:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
